Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors. 2012

Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
Zydus Research Centre, Sarkhej-Bavla, N.H. 8A Moraiya, Ahmedabad 382210, India; Department of Chemistry, Faculty of Science, M.S. University of Baroda, Vadodara 390002, India. dipam.patel@rediffmail.com

A novel series of pTyr mimetics containing triaryl-sulfonamide derivatives (5a-r) are reported as potent and selective PTP1B inhibitors. Some of the test compounds (5o and 5p) showed excellent selectivity towards PTP1B over various PTPs, including TCPTP (in vitro). The lead compound 5o showed potent antidiabetic activity (in vivo), along with improved pharmacokinetic profile. These preliminary results confirm discovery of highly potent and selective PTP1B inhibitors for the treatment of T2DM.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
October 2006, Bioorganic & medicinal chemistry letters,
Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
March 2006, Bioorganic & medicinal chemistry letters,
Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
June 2007, Journal of medicinal chemistry,
Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
August 2011, Bioorganic & medicinal chemistry,
Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
January 2024, Journal of medicinal chemistry,
Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
June 2018, Bioorganic & medicinal chemistry letters,
Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
July 2022, ACS medicinal chemistry letters,
Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
July 2016, ACS medicinal chemistry letters,
Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
June 2021, ACS medicinal chemistry letters,
Dipam Patel, and Mukul Jain, and Shailesh R Shah, and Rajesh Bahekar, and Pradip Jadav, and Amit Joharapurkar, and Nirav Dhanesha, and Mubeen Shaikh, and Kalapatapu V V M Sairam, and Prashant Kapadnis
May 2016, ACS medicinal chemistry letters,
Copied contents to your clipboard!